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Abstract Recent data suggest that tumor persistence and re-
currence could be caused by the presence of cancer stem cells
(CSCs). Aldehyde dehydrogenase 1 (ALDH1) has been im-
plicated in cancer pathogenesis and used as a CSCmarker. We
previously reported that cervical carcinoma contains a small
subpopulation of cells expressing ALDH1 [1]. In this study,
we used small interfering RNA to suppress ALDH1 expres-
sion and introduced an ALDH1 reporting vector into HeLa
cells followed by various in vitro assays. We showed that
knockdown of ALDH1 expression reduced the cell migration
ability of HeLa cells, whereas augmented expression of
ALDH1 increased cell migration. However, there was no dif-
ference in the cellular proliferation, apoptosis, cell cycle, and
invasion. These results indicate that ALDH1 is directly in-
volved in HeLa migration.
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Introduction
Cervical cancer is the third most common cancer in women
worldwide and the most frequently occurring cancer of the
female reproductive tract [2]. HPV infection has been shown
to play a critical role in its etiology; however, it is not suffi-
cient. Despite recent advances in the early detection and diag-
nosis of cervical cancer, the incidence is increasing and cur-
rent treatments are unsatisfactory.
A number of studies have shown that a small proportion of
tumor cells, designated as cancer stem cells, were capable of
self-renewal and played a decisive role in tumor formation and
growth [3, 4]. Additionally, tumor recurrence after conven-
tional therapy has been suggested to result from the presence
of these slow-cycling cells, which are capable of initiating and
sustaining neoplastic growth [5, 6]. The resistance of cancer
stem cells (CSCs) to conventional chemotherapy and radio-
therapy has been attributed to cellular mechanisms such as
multidrug resistance, quiescence, enhanced DNA repair abil-
ities, and anti-apoptotic mechanisms [7]. Dysregulation of key
signaling pathways such as the Wnt, Hedgehog, Notch, and
TGF-β/BMP pathways plays an important role in modulating
tumorigenesis as well as in stem cell function [8]. These stud-
ies suggest that identification and targeting cancer stem cells
are key aspects to optimizing cancer therapy. CSCs have been
isolated and cultured as structured spheroids in the presence of
serum and growth factors. Several markers have been pro-
posed to identify and isolate cancer stem cells including
CD133, CD44, CD24, CD90, CD34, CD117, CD20, and al-
dehyde dehydrogenase (ALDH1) [7, 9], a cytosolic enzyme
that is responsible for the oxidation of retinaldehydes to
retinoids [10, 11].
Some members of the ALDH super-family play key
roles in the enzymatic detoxification of endogenous and
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metabolic molecules such as retinoic acid or gamma-
aminobutyric acid [12]. Thus, ALDH gene mutations lead to
defective metabolism and provide the basic features of diseases
such as gamma-hydroxybutyric aciduria, pyridoxine-
dependent seizures, Sjögren syndrome, or type II
hyperprolinemia [13]. Recent studies have shown that
ALDH1 is a cancer stem cell marker and that its presence
strongly correlates with tumor malignancy and self-renewal
properties of stem cells in different tumors, including breast
cancer, hepatoma, and colon and lung cancer [14–17].We have
previously reported that expression of ALDH1 was found in
24.77% of cervical carcinoma by immunohistochemical stain-
ing. Additionally, flow cytometric analysis, qRT-PCR, and
Western blot confirmed the presence of small subpopulations
of ALDH1-positive cells. To examine the significance, we reg-
ulated and monitored ALDH1 gene expression by real time
(RT)-PCR and Western blotting in HeLa cells. There was no
change in the proliferation, apoptosis, and cell cycle after al-
teration of ALDH1 expression. Additionally, we demonstrated
that reduction of ALDH1 led to markedly decreased migration,
whereas restoration improved migration, suggesting that




The HeLa human cervical adenocarcinoma cell line was
purchased from the American Type Culture Collection
and main ta ined in RPMI 1640 medium (Li fe
Technologies) supplemented with 10 % fetal bovine se-
rum (Invitrogen).
siRNA transfection
Three small interfering RNAs (siRNAs) targeting specific se-
quences of ALDH1 (NM_017617) and a scrambled siRNA
(not homologous to any gene) as a negative control were syn-
thesized by GenePharma (Shanghai, China). Searches of the
genome database (BLAST, SSEARCH) were conducted to
ensure that these sequences would not target other genes.
Preliminary experiments indicated that, of the three siRNAs,
the siRNA targeting the specific sequence (sense′-CCAAAG
UCCUGGAGGUUGAdTdT-3′ and antisense 3′-dTdTGGU
UUCAGGACCUCCAACU-5′) yielded the greatest downreg-
ulation of ALDH1 expression (data not shown). This siRNA
was selected for further investigation. A non-targeting siRNA
(nt-siRNA), which did not target any known gene, was used as
a negative control.We performed siRNA transfection efficien-
cy assays using varying concentrations of siRNA and deter-
mined that 25 nmol of siRNA provided optimal transfection
efficiency (data not shown). In each experiment, the nt-siRNA
t r ans f e c t i on , pa r t i c l e s t imu l a t i on -on ly g roups
(nontransfection, particle stimulation only), and the negative
control (NC=nontransfection and nonparticle stimulation)
groups were included as controls. HeLa cells were seeded into
6-well plates (4–5×104 cells/well) and cultured in 2 mL of
basic culture medium containing 10 % FBS until the cells
were 70 % confluent. The siRNA-Lipofectamine™ 2000
complex was pre-mixed according to the manufacturer’s in-
structions and added to the 6-well plates. The results were
confirmed by real-time RT-PCR.
Plasmids and primers
Human ALDH1 cDNA was cloned into the pIRES2-vector
(Clontech, Santa Clara, CA) between the BamHI and the
HindIII restriction sites (pIRES2/ALDH1), and a corrective
construct was verified by DNA sequencing. The pIRES2/
ALDH1 construct was transfected into HeLa cells using
Lipofectamine plus reagent (Invitrogen, San Diego, CA) fol-
lowing the manufacturer’s instructions. The cells were cul-
tured in the presence of 1 mg/mL of G418 to establish stable
cell lines. The expression of ALDH1 was confirmed by
Western blot and reverse transcriptase polymerase chain
reaction.
Quantitative real-time PCR
All the reactions were performed in a 20-μL reaction volume
in triplicate by SYBR Green Real-time PCR Universal
Reagent (GenePharma Co., Ltd.) and MX-3000P Real-time
PCR equipment (Stratagen). Standard curves were generated,
Fig. 1 Expression of ALDH1 in various cells. a The mRNA expression
of ALDH1 in the cells without treatment, the cells with non-targeting
siRNA and the cells with siRNA targeting the specific sequence. b The
detection of ALDH1 mRNA levels in cells without any treatment, the
cells just with vector and cells with a pIRES2/ALDH1 construct
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and the relative amount of ALDH1 was normalized to 18S
RNA (2−ΔΔCt). The ALDH1 expression fold change was
evaluated using 2−ΔΔCt. The primers are ALDH1 (forward,
5′-CTGCTGGCGACAATGGAGT-3′; reverse, 5′-GTCAGC
CCAACCTGCACAG-3′) and 18S rRNA (forward 5′-CCTG
GATACCGCAGCTAGGA-3′ and reverse 5′-GCGGCGCA
ATACGAATGCCCC -3′). These primers yielded 230- and
112-bp products, respectively.
Fig. 2 The MTT assay to evaluate cell proliferation. a The OD value of
the cells without any treatment, the cells with non-targeting of siRNA and
the cells with siRNA targeting the specific sequence. b The OD value of
the cells without treatment, the cells with vector and the cells with a
pIRES2/ALDH1 construct
Fig. 3 Cell death was monitored
by Annexin V staining and flow
cytometry. The right lower
quadrant of each plot contains
early apoptotic cells, whereas the
right upper quadrant contains late
apoptotic cells. This experiment
was repeated on three
independent occasions, and
similar results were obtained each
time. a The cells without any
treatment, cells with non-
targeting siRNA and cells with
siRNA targeting the specific
sequence. b The cells without any
treatment, cells just with vector
and cells with pIRES2/ALDH1
construct. c Each bar represents
mean values±SE from three
independent experiments for cells
without any treatment, with non-
targeting siRNA and with siRNA
targeting the specific sequence. d
Each bar represents mean values
±SE from three independent
experiments for cells without any
treatment, cells just with vector
and cells with pIRES2/ALDH1
construct
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Cell proliferation assays
The cell survival was assessed using the 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-
2H-tetrazolium (MTS) assay (Sigma). For the MTS assay
(Promega), 1×104 cells/well were seeded in triplicate in a
96-well plate for each cell line. At 12, 24, and 48 h, 20 μL
of MTS reagent was added to each well and incubated for 1 h
at 37 °C; the results were analyzed by a plate reader at 490 nm.
The sample data were normalized to the background readings
of media only.
Cell cycle analysis
Forty-eight hours after transfection, the cells were harvested
and fixed in 70 % ice cold ethanol and followed by RNase A
treatment, stained with 50 lg/mL of propidium iodide for the
DNA content analysis by flow cytometry on a FACS Calibur
system (EPICS ALTRA, Beckman Coulter, Fullerton, CA).
The data were collected and processed using FlowJo FACS
analysis software (Tree Star, Ashland, OR).
Apoptosis assays
The cell pellets were resuspended in Annexin V-FLUOS stain-
ing solution (Roche Molecular Biochemicals) and incubated
for 15 min at room temperature. The samples were then ana-
lyzed on a FACS Calibur system (EPICS ALTRA, Beckman
Coulter, Fullerton, CA).
Transwell cell migration assay
Forty-eight hours after transfection, the cells were resuspend-
ed in serum-free RPMI 1640 medium, and 5×104 cells were
added to the upper chamber of Matrigel-coated 24-well plates
(8-μm pore size, Corning, Corning, NY). The lower compart-
ment was filled with RPMI 1640 medium containing 20 %
FBS. After 24 h, the cells that had not migrated were removed
from the upper face of the filters using cotton swabs, and the
cells that had migrated to the lower surface of the filters.
Statistical analyses
The normally distributed continuous variables were compared
by a one-way analysis of variance (ANOVA). When signifi-
cance between the groups was apparent, multiple comparisons
of the means were performed using the Bonferroni procedure
with type I error adjustment. The data are presented as the
means±standard deviation (SD). P values of less than 0.05 were
deemed significant. Repeatedmeasurements with a linear mixed
model were conducted to determine the group effect in the
change of theMTSOD values among the groups. The statistical
Fig. 4 The cell cycle distribution of the cells was analyzed by FACS. a The cells without any treatment, cells with non-targeting siRNA and cells with
siRNA targeting the specific sequence. b The cells without any treatment, cells just with vector and cells with pIRES2/ALDH1 construct
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assessments were two-sided and evaluated at the 0.05 level of
significant difference. The statistical analyses were performed
using SPSS 15.0 statistical software (SPSS, Inc., Chicago, IL).
Results
ALDH1 gene expression in HeLa cells was successfully
disturbed by transfecting siRNA or overexpressing
plasmid
RNAi technology was employed to silence the ALDH1 ex-
pression. Real-time PCR and Western blot were performed to
quantify ALDH1 expression. Endogenous ALDH1 mRNA
expression (Fig. 1a) were significantly lowered by RNAi
(HeLa-ALDH1-RNAi) than by the control transfections
(HeLa-NCi) and HeLa cells. To increase the ALDH1
expression, the cells were stably transfected with an ALDH1
expression construct. After transfection and G418 selection,
the ALDH1 mRNA (Fig. 1b) expression levels in the stably
transfected cells (HeLa-ALDH1) were much higher than in
the HeLa cells.
No effect of ALDH1 on proliferation, apoptosis, and cell
cycle
As shown in Fig. 2a, knockdown of ALDH1 using the
oligonuclear sequences resulted in no significant decrease
and no significant increase in the HeLa cell proliferation
(Fig. 2a), apoptosis (Fig. 3a, c), and cell cycle (Fig. 3a) com-
pared to the empty vector-transfected cells. Similarly, no ob-
vious alteration of the HeLa cells was found in the ALDH1
overexpressing cells in comparison to that in the control
sequence-transfected group (Figs. 2b, 3b, c, and 4b).
Fig. 5 The Transwell analysis of migration. a The cells without any
treatment, cells with non-targeting siRNA and cells with siRNA
targeting the specific sequence. b The cells without any treatment, cells
just with vector and cells with pIRES2/ALDH1 construct. c Each bar
represents mean values±SE from three independent experiments for
cells without any treatment, with non-targeting siRNA and with siRNA
targeting the specific sequence. d Each bar represents mean values±SE
from three independent experiments for cells without any treatment, cells
just with vector and cells with pIRES2/ALDH1 construct
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ALDH1 influences HeLa cell migration in vitro
To examine the effect of ALDH1 on the mobility of HeLa
cells, the migration was measured by Transwell assays. We
showed that the SiRNA-transfected HeLa cells had lower mi-
gration rates than the control (Fig. 5a, c), whereas the HeLa-
ALDH1-positive cells had significantly higher migration rates
than their control cells (Fig. 5b, d), suggesting that ALDH1 is
an effective target for treating cervical cancer metastases.
Discussion
Recurrence and metastasis are the most important fac-
tors affecting the prognosis of patients with cervical
cancer [18]. Developing molecular biomarkers to detect
cancer, predicting disease progression, and monitoring
therapeutic response would be beneficial. ALDH1 is a
detoxifying enzyme responsible for the oxidation of ret-
inol to retinoic acid, and it has a role in the early
differentiation of stem cells.
Recent studies showed that ALDH1 expression was
associated with tumor cell metastasis in vivo [19, 20].
According to the report of the Sidney Kimmel
Comprehensive Cancer Center in the USA, a high
ALDH expression is associated with worse overall sur-
vival in patients who have undergone resection for
early-stage disease. The European Society for Medical
Oncology (ESMO) has established Practice Guidelines
that suggest that enhanced clonogenic growth of
ALDH+ cancer cells has an important role in the
long-term outcome of patients diagnosed with pancreatic
adenocarcinoma by mediating or even stimulating cancer
dissemination throughout the abdominal cavity and re-
sistance to chemotherapy with 5-fluorouracil (5-FU) or
gemcitabine [21].
To confirm whether ALDH1 was involved in cervical
cancer metastasis, we performed a Transwell migration
assay in vitro to investigate the effect of ALDH1 on
HeLa cell mobility. Similar to those of previous studies,
our results showed that the migrated rate of cells was
concordant with ALDH1 expression. However, our re-
sults indicated that ALDH1 has no relationship with cell
proliferation, which was not consistent with previous
reports. Additionally, we found that the rates of apopto-
tic cells and cell cycle distribution did not present any
significant alteration. The finding suggested that
ALDH1 might participate in the tumorigenesis of cervi-
cal cancer through pathways other than the promotion
of cell growth and obstruction of apoptosis. ALDH1
might be involved in metastasis in cervical cancer pa-
tients. ALDH1 could be used as a therapeutic target.
Conclusion
Our results demonstrated that ALDH1 might be involved in
cervical cancer metastasis. Further experiments in vivo are
necessary to clarify that ALDH1 might be a promising target
and prognostic predictor for treating cervical cancer
metastases.
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